Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.
News|Videos|January 17, 2025
Upcoming Research Related to DLX-001 for Major Depressive Disorder
Author(s)Aaron Koenig, MD
Key Takeaways
- DLX-001 is a novel neuroplastogen under investigation for treating major depressive disorder (MDD).
- Phase 1 study in healthy volunteers is complete; phase 1b translational study results are expected by mid-2025.
Want to stay in the loop on the latest novel neuroplastogen for major depressive disorder, DLX-001? Check out this update.
Advertisement
Aaron Koenig, MD, the chief medical officer of Delix Therapeutics, shares what you should be on the lookout for related to the novel neuroplastogen, DLX-001, currently under study for patients with MDD.
Researchers have completed the phase 1 study in healthy volunteers. Now, they will begin further research to confirm this potential treatment's effectiveness.
- Delix has started dosing in a single-site, phase 1b translational study. Results will be shared mid 2025.
- Also around mid 2025, researchers will start the phase 2 randomized controlled trial in patients with MDD at multiple sites.
See more on DLX-001 from Dr Koenig
Dr Koenig currently serves as chief medical officer for Delix Therapeutics, is a diplomate of the American Board of Psychiatry and Neurology, and retains active board certification in adult and geriatric psychiatry.
Advertisement
Related to this article
Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.
FDA aligns with Cognition on a phase 3 zervimesine trial for Lewy body dementia, testing 100 mg daily for 9 months to target hallucinations.
UK AD-SMART platform trial speeds Alzheimer disease treatment discovery by testing multiple repurposed drugs at once across NHS sites, aiming to protect memory and quality of life.
The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
Phase 2 data show RAP-219 eases acute bipolar mania with significant YMRS gains and encouraging tolerability, setting the stage for FDA talks and phase 3 plans.
Neurocrine launches a phase 2 trial of once-daily NBI-'567, testing a selective muscarinic agonist to boost cognition in mild to moderate Alzheimer disease.
Phase 2 trial finds bezisterim shows safety and symptom gains in long COVID, with strongest benefits for severe fatigue, PEM, and cognitive issues.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Daridorexant, Orexin Receptor Agonist, Shows Positive Results in Pediatric Insomnia
2
Synapse-Level Mapping Could Reveal How Disrupted Brain Circuits Lead to Psychiatric Disorders
3
Dementia Pipeline Update: Phase 2 and 3 Developments in Alzheimer Disease and Lewy Body Dementia
4
Food Noise and GLP-1 Drugs: What Research Reveals About Motivation and Appetitive Drive
5